Literature DB >> 15557195

Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis.

Paulo Fontoura1, Peggy P Ho, Jason DeVoss, Binhai Zheng, Byung J Lee, Brian A Kidd, Hideki Garren, Raymond A Sobel, William H Robinson, Marc Tessier-Lavigne, Lawrence Steinman.   

Abstract

Nogo-66, the extracellular 66 aa loop of the Nogo-A protein found in CNS myelin, interacts with the Nogo receptor and has been proposed to mediate inhibition of axonal regrowth. It has been shown that immunization with Nogo-A promotes recovery in animal models of spinal cord injury through induction of Ab production. In this report, studies were performed to characterize the immune response to Nogo-66 and to determine the role of Nogo in experimental autoimmune encephalomyelitis (EAE). Immunization of EAE-susceptible mouse strains with peptides derived from Nogo-66 induced a CNS immune response with clinical and pathological similarities to EAE. The Nogo-66 peptides elicited strong T cell responses that were not cross-reactive to other encephalitogenic myelin Ags. Using a large scale spotted microarray containing proteins and peptides derived from a wide spectrum of myelin components, we demonstrated that Nogo-66 peptides also generated a specific Ab response that spreads to several other encephalitogenic myelin Ags following immunization. Nogo-66-specific T cell lines ameliorated established EAE, via Nogo-66-specific Th2 cells that entered the CNS. These results indicate that some T cell and B cell immune responses to Nogo-66 are associated with suppression of ongoing EAE, whereas other Nogo-66 epitopes can be encephalitogenic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557195     DOI: 10.4049/jimmunol.173.11.6981

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  New Insights into the Roles of Nogo-A in CNS Biology and Diseases.

Authors:  Yun-Peng Sui; Xiao-Xi Zhang; Jun-Lin Lu; Feng Sui
Journal:  Neurochem Res       Date:  2015-08-13       Impact factor: 3.996

2.  Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation.

Authors:  Angelo A Chora; Paulo Fontoura; Andreia Cunha; Teresa F Pais; Sílvia Cardoso; Peggy P Ho; Lowen Y Lee; Raymond A Sobel; Lawrence Steinman; Miguel P Soares
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

3.  The Nogo/Nogo Receptor (NgR) Signal Is Involved in Neuroinflammation through the Regulation of Microglial Inflammatory Activation.

Authors:  Yinquan Fang; Jun Yan; Chenhui Li; Xiao Zhou; Lemeng Yao; Tao Pang; Ming Yan; Luyong Zhang; Lei Mao; Hong Liao
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

4.  Silencing Nogo-A promotes functional recovery in demyelinating disease.

Authors:  Yuhong Yang; Yue Liu; Ping Wei; Haiyan Peng; Ryan Winger; Rehana Z Hussain; Li-Hong Ben; Petra D Cravens; Anne R Gocke; Krishna Puttaparthi; Michael K Racke; Dana M McTigue; Amy E Lovett-Racke
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 5.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 6.  IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis.

Authors:  Bernadette Pöllinger
Journal:  J Mol Med (Berl)       Date:  2012-01-10       Impact factor: 4.599

7.  Epithelial reticulon 4B (Nogo-B) is an endogenous regulator of Th2-driven lung inflammation.

Authors:  Paulette L Wright; Jun Yu; Y P Peter Di; Robert J Homer; Geoffrey Chupp; Jack A Elias; Lauren Cohn; William C Sessa
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

Review 8.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10

10.  Matrine Treatment Blocks NogoA-Induced Neural Inhibitory Signaling Pathway in Ongoing Experimental Autoimmune Encephalomyelitis.

Authors:  Quan-Cheng Kan; Hui-Jun Zhang; Yuan Zhang; Xing Li; Yu-Ming Xu; Rodolfo Thome; Ming-Liang Zhang; Nan Liu; Yao-Juan Chu; Guang-Xian Zhang; Lin Zhu
Journal:  Mol Neurobiol       Date:  2016-12-09       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.